伊立替康(Irinotecan,CPT-11)是一种治疗癌症的化疗药物,主要代谢产物为7-乙基-10羟基喜树碱(7-Ethyl-10-hydroxycamptothecin,SN38).课题组实验筛选结果表明伊立替康对ataxin-3核质转运有潜在影响.通过免疫荧光、微孔过滤分析以及Preto...伊立替康(Irinotecan,CPT-11)是一种治疗癌症的化疗药物,主要代谢产物为7-乙基-10羟基喜树碱(7-Ethyl-10-hydroxycamptothecin,SN38).课题组实验筛选结果表明伊立替康对ataxin-3核质转运有潜在影响.通过免疫荧光、微孔过滤分析以及PretoBlue细胞活性检测等方法,探讨伊立替康对ataxin-3质核分离、突变ataxin-3形成的聚集体以及spinocerebellar ataxia type 3(SCA3)细胞活性的影响.结果表明伊立替康在10μM处理浓度时能够减少ataxin-3进入细胞核,但对蛋白聚集体没有影响;伊立替康在0.001μM或100μM处理浓度时,对SCA3细胞具有细胞毒性作用.本研究阐释了伊立替康对SCA3细胞模型的影响,揭示了旧药新靶点,为其他神经退行性疾病的致病机理和治疗药物研发提供新依据.展开更多
Machado-Joseph disease,or spinocerebellar ataxia type 3(SCA3),represents the most common autosomal dominant cerebellar ataxia worldwide.Despite its progressive and debilitating nature,disease-modifying therapies remai...Machado-Joseph disease,or spinocerebellar ataxia type 3(SCA3),represents the most common autosomal dominant cerebellar ataxia worldwide.Despite its progressive and debilitating nature,disease-modifying therapies remain elusive.Repetitive transcranial magnetic stimulation(rTMS)has emerged as a promising non-invasive intervention;however,its clinical application has been hindered by inconsistent protocols and a lack of mechanistic understanding.A recent landmark study published in Brain Stimulation by Chen et al.addressed these challenges by combining a high-dose intermittent theta-burst stimulation(iTBS)protocol with concurrent transcranial magnetic stimulation-electroencephalography(TMS-EEG).This commentary provides an in-depth analysis of their findings,highlighting the restoration of cerebello-cortical inhibition(CBI)as a key therapeutic mechanism.Furthermore,we discuss the broader implications of this work,proposing that future translational research should integrate accelerated iTBS(aiTBS)paradigms,cortical response measurements(CRM),and individualized neuro-navigation to establish a new era of precision neuromodulation for ataxia.展开更多
文摘伊立替康(Irinotecan,CPT-11)是一种治疗癌症的化疗药物,主要代谢产物为7-乙基-10羟基喜树碱(7-Ethyl-10-hydroxycamptothecin,SN38).课题组实验筛选结果表明伊立替康对ataxin-3核质转运有潜在影响.通过免疫荧光、微孔过滤分析以及PretoBlue细胞活性检测等方法,探讨伊立替康对ataxin-3质核分离、突变ataxin-3形成的聚集体以及spinocerebellar ataxia type 3(SCA3)细胞活性的影响.结果表明伊立替康在10μM处理浓度时能够减少ataxin-3进入细胞核,但对蛋白聚集体没有影响;伊立替康在0.001μM或100μM处理浓度时,对SCA3细胞具有细胞毒性作用.本研究阐释了伊立替康对SCA3细胞模型的影响,揭示了旧药新靶点,为其他神经退行性疾病的致病机理和治疗药物研发提供新依据.
基金supported by grants from the Open Research Fund of the Zhejiang Key Laboratory of Precision Psychiatry(2025A2)the Natural Science Foundation of Zhejiang Province(LY23C090002)。
文摘Machado-Joseph disease,or spinocerebellar ataxia type 3(SCA3),represents the most common autosomal dominant cerebellar ataxia worldwide.Despite its progressive and debilitating nature,disease-modifying therapies remain elusive.Repetitive transcranial magnetic stimulation(rTMS)has emerged as a promising non-invasive intervention;however,its clinical application has been hindered by inconsistent protocols and a lack of mechanistic understanding.A recent landmark study published in Brain Stimulation by Chen et al.addressed these challenges by combining a high-dose intermittent theta-burst stimulation(iTBS)protocol with concurrent transcranial magnetic stimulation-electroencephalography(TMS-EEG).This commentary provides an in-depth analysis of their findings,highlighting the restoration of cerebello-cortical inhibition(CBI)as a key therapeutic mechanism.Furthermore,we discuss the broader implications of this work,proposing that future translational research should integrate accelerated iTBS(aiTBS)paradigms,cortical response measurements(CRM),and individualized neuro-navigation to establish a new era of precision neuromodulation for ataxia.
